Evidence map›Paper›PMID 35279419›Full record

ArticleClinical genitourinary cancer2022

Predictors of Survival in Patients Undergoing Surgery for Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus.

Alberto C Pieretti, Manuel Ozambela, Mary E Westerman, Graciela M Nogueras-Gonzalez, Luis A Segarra, Niki M Zacharias, Ara Vaporciyan, Wayne Hofstetter, Tam Huynh, Saad Aldousari and 2 more

Abstract read
In one paragraph

Article in Clinical genitourinary cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alberto C PierettiDepartments of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Manuel OzambelaDepartments of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Mary E WestermanDepartments of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Graciela M Nogueras-GonzalezDepartments of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Luis A SegarraDepartments of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Niki M ZachariasDepartments of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Ara VaporciyanThoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.
Wayne HofstetterThoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.
Tam HuynhThoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.
Saad AldousariDepartments of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Surena F MatinDepartments of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jose A KaramDepartments of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: jakaram@mdanderson.org.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

introductionSurgical resection of renal cell carcinoma (RCC) with inferior vena cava (IVC) thrombus is a complex procedure with significant morbidity. Patient selection is critical to determining whether the benefits of the procedure outweigh the risks. In this study, we identified and stratified the risk factors that were associated with overall survival (OS) and recurrence-free survival (RFS) in patients undergoing surgical resection of RCC with IVC thrombus.

methodsWe identified all patients with RCC with IVC tumor thrombus (stages cT3b and cT3c) who had undergone radical nephrectomy with tumor thrombectomy between December 1, 1993 and June 30, 2009. Kaplan-Meier method was used to estimate OS and RFS. Cox proportional hazards models were used to determine the association between risk factors and OS. Patients were stratified into 3 groups based on the number of risk factors present at diagnosis.

resultsTwo hundred twenty-four patients were included in the study. A total of 45.3% of patients had metastasis at presentation, 84.5% had cT3b, and 90.2% had clear cell RCC. cT3c, cN1, and cM1 were significantly associated with the risk of death. Group 1 patients (0 risk factors) had a median OS duration of 77.6 months (95% CI 50.5-90.4), group 2 (1 risk factor) 26.0 months (95% CI 19.5-35.2), and group 3 (≥2 risk factors) 8.9 months (95% CI 5.2-12.9; P < .001).

conclusionsStratification of patients with RCC and IVC thrombus by risk factors allowed us to predict survival duration. In patients with ≥2 risk factors, new treatment strategies with preoperative systemic therapy may improve survival.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsVenous ThrombosisHumansNephrectomyRetrospective StudiesThrombectomyVena Cava, InferiorNomogramOutcomesOverall survivalPatient selectionRecurrence-free survivalThrombectomy

Identifiers

PMID35279419
PMCPMC9486579

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.